Compare AbbVie Inc (ABBV) vs Direxion Daily TSLA Bull 2X Shares (TSLL) Price & Performance

AbbVie (ABBV) trades at $254.44, showing slight daily weakness but maintaining a bullish technical structure with strong institutional support. The company has consistently beaten earnings expectations in recent quarters, with Q1 2026 EPS of $2.65 exceeding the $2.59 estimate. Revenue growth is accelerating, reaching $61.16B in 2025, while the immunology portfolio (Skyrizi, Rinvoq) successfully offsets Humira declines. Analyst consensus remains strongly positive with 68% buy ratings and a $266.33 price target.

The outlook is constructive with robust pipeline developments and dividend growth, though elevated valuation multiples (P/E 124.83, P/B 245.29) and looming patent cliffs in the 2030s present risks. Net income margin compression from 20.38% in 2022 to 6.9% in 2025 requires monitoring, but strong cash generation ($19.03B operating cash flow) supports continued shareholder returns.

TSLL trades at $13.95, up 13.41% in the last 24 hours, with technical indicators showing a bullish trend from moving averages while oscillators remain neutral. Support levels are established at $13 and $12, with resistance near $15. Recent news highlights continued investor interest in leveraged ETF strategies tied to high-growth sectors like Tesla.

The outlook for TSLL is cautiously optimistic, driven by strong technical momentum and sector interest, but risks include market volatility and dependency on underlying asset performance. Investors should weigh the potential for amplified returns against the inherent leverage risks in the ETF structure.